Nieves

Back to #Twitter in time for the high level event of hosting @OncoBellmunt from @harvardmed for the @JulesBordet @ULBruxelles Meet the Oncology Expert seminar on #BladderCancer. A privilege and a great pleasure!

🚩POSTER SESSION @ASCO #ASCO19 📆Monday 🕐 ‼️A new study characterizes the safety of checkpoint inhibitors in patients w autoimmune disorders, providing hope for more advanced care options for such pts @NMartinezChanza @DrChoueiri @LaurenCHarshman meetinglibrary.asco.org/record/172119/…

Amazing poster by our star fellow @anis_a_hamid mentored by @ChrisSweens1 about genomic predictors of CRPC clinical benefit in next generation hormonal therapy! @mishabeltran @AtishChoudhury @ASCO #ASCO19 @WeillCornell @DanaFarber @DanaFarberNews

Not half bad 👏 @ChrisSweens1 #ENZAMET @ANZUPtrials @DanaFarberNews #ASCO19

Stellar speakers for the upcoming cycle of “Meet the Oncology Expert” seminars at @JulesBordet

@emilykatehayes 🙏@emilykatehayes for sharing! ☑️ Heterogeneity in HPD defn across studies (different TGR formulas + TGR ratio cutoffs) ☑️ New lesions not accounted for in most defns ☑️ Underlying biology remains unclear @NMartinezChanza @LaurenCHarshman @OsamaRahma2 @eric_ko_mdphd @DrChoueiri

Collaboration +persistence +awesome RCC international community —congrats ⁦@LaurenCHarshman⁩ ⁦@NMartinezChanza⁩ and everyone ! ⁦@DanaFarber⁩ ⁦@DanaFarberNews⁩ thelancet.com/journals/lanon…

Article online: retrospective, cohort study on #cabozantinib in advanced non-clear-cell #renalcellcarcinoma thelancet.com/journals/lanon…

Thanks for highlighting. Multi-institutional collaboration. Thanks to all included! thelancet.com/journals/lanon…

Pre-existing autoimmune disorders: safety and activity of #immunotherapy in #RCC pts Great study @NMartinezChanza @xiaoweimd @BradMcG04 @DrChoueiri @LaurenCHarshman @DanaFarber #IKCS18

Thanks!! And also a big thanks to my mentor @LaurenCHarshman & team @DanaFarber

Excellent example of persistent & perseverance by @LaurenCHarshman with #EA8143 PROSPER trial that is actively ongoing in numerous sites in US and soon Canada. Way to go! @eaonc @DanaFarber @DrChoueiri @montypal @SuzanneColeMD @HamidEmamekhoo @BradMcG04 @kcCURE @KCA_Journal

@anis_a_hamid & @ChrisSweens1 Congrats!! Nice job

Study from @sloan_kettering shows that ~20% of non-cc mRCC pts have germline mutations. Editorial in @JAMAOnc by @kcooney1234 raises question whether all non-cc mRCC pts should be referred for germline testing? bit.ly/2ucJd20 @neerajaiims @montypal

#PDG4 team supporting @CapuBaldini #MCCRWorkshop #voteforCapu #spanishoncologist @NMartinezChanza @pmartinromano @GustaveRoussy twitter.com/pmartinromano/…

@Daniel_J_George shootout for #PROSPER #RCC why perhaps treating before surgery makes sense in IO trials #neoantigens @LaurenCHarshman @ASCO @allaf_mo #ASCO18

Proud of @NMartinezChanza sharing the results from largest dataset on #cabozantinib in non-clear cell #kidneycancer Many great colleagues' contributed! #asco18 @danafarber

TP53, PTEN, RB1 associated with poor prognosis in CSPC and CRPC by @anis_a_hamid & @ChrisSweens1. Amazing work! @DanaFarber @VanAllenLab @AtishChoudhury @belowthebelt_md

Congrats @Dominick_Bosse (w mentorship from @DrChoueiri) on association between key #KidneyCancer genes (eg PBRM1, BAP1) and clinical outcome. Nice summary from @EJonasch @MDAndersonNews.

@sumitshahMD @LaurenCHarshman @StanfordCancer @DanaFarber Thanks @sumitshahMD It was great collaborating with you on this research. Stronger together!

Important multi-institutional effort led by @NMartinezChanza and @LaurenCHarshman looking at cabozantanib in non-clear cell RCC. Collaboration is key! Proud to have contributed. #ASCO18 #mRCC @StanfordCancer @DanaFarber